nab-paclitaxel, gemcitabine

DRUG2 trials

Sponsors

Fudan University, Akeso

Conditions

Metastatic Pancreatic Ductal AdenocarcinomaPancreatic Cancer Metastatic

Phase 1

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Active, not recruitingNCT06646055

AkesoMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2025-01-21End: 2027-12-30Target: 110Updated: 2026-03-09

Phase 2

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

RecruitingNCT05969171

Fudan UniversityPancreatic Cancer Metastatic

Start: 2023-12-05End: 2026-12-31Target: 65Updated: 2025-07-30

Related Papers

Abstract CT146: Sequential treatment with surufatinib combined with gemcitabine and nab-paclitaxel (AG) or AG alone as first-line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC) after 6 weeks of AG induction therapy: A two-cohort, exploratory phase II study

Cancer Research2026-04-17